Introduction
The role of proprotein convertase subtilisin/kexin Type 9 (PCSK9) in the regulation of the low-density lipoprotein (LDL)-receptor and plasma cholesterol was identified in 2003. 1 This seminal discovery led to the rapid exploitation of PCSK9 as a drug target. Fifteen years later, investigators have completed two large outcomes trials of monoclonal antibody inhibitors of PCSK9 (PCSK9Is Table 1) . Treatment of patients with these agents has been remarkably successful in achieving lower plasma concentrations of LDL-cholesterol (LDL-C) than had ever previously been attainable with lipidlowering therapy. Therefore, in addition to the 'headline' event-rate reduction results of these trials, which will certainly inform clinical practice, scrutiny of the trial data can yield more general information about lipidlowering therapy. This commentary will briefly discuss what we have learned from outcome trials of evolocumab and alirocumab, and what the future holds for these agents.
2. What have we learned from PCSK9I outcomes trials, and how has practice changed?
The addition of alirocumab and evolocumab to lipid-lowering therapy with statins (with or without ezetimibe), has enabled the effective management of patient groups for whom achievement and maintenance of lipid-targets were previously extremely difficult. In particular, the very large reductions in LDL-C elicited by PCSK9 inhibitors have been used to manage patients with familial hypercholesterolaemia (FH). Using these agents, it has been possible to meet LDL-targets for most of this population, and additionally for some of them (even for 93%) it is now possible to entirely replace LDL-C apheresis (or to reduce the frequency of procedures) using PCSK9 inhibitor therapy. In several European countries, FH patients are the only group for whom reimbursement for PCSK9 inhibitors is allowed ( Figure 1 ). The availability of an effective therapeutic approach to FH has in fact led to a revival in interest in this condition 4 in many countries in which knowledge of this condition (and other genetically based lipid disorders) was very poor. Hopefully this will lead to redoubled efforts to identify undiagnosed FH patients. Statin intolerance, in particular statin-associated muscle symptoms is an important cause of statin non-adherence, discontinuation, and suboptimal lipid management. 5, 6 Inhibitors of PCSK9 have also prompted discussion on the definition of statin intolerance and its effective diagnosis. 7 Additionally these agents have shown promise in the effective management of plasma lipid concentrations in statin intolerant patients, for whom there was previously no effective therapy. [5] [6] [7] The GAUSS-3 trial found that in patients with confirmed statin intolerance, evolocumab was associated with a 53% reduction in LDL-C at 24 weeks. Muscle symptoms were reported in only 21% of evolocumab-treated patients. 8 Similarly, in the ODYSSEY-alternative trial, alirocumab reduced mean LDL-C by 45% at 24 weeks. 9 In both cases, PCSK9 inhibition was superior to ezetimibe. The demonstration of the concept of effective lipidlowering in statin intolerant patients has led to trials investigating alternative lipid-lowering therapies such as bempedoic acid and to look for the other alternative therapies that might reduce LDL-C in patients with high cardiovascular (CV) risk.
10,11
The extremely low plasma concentrations of LDL-C achieved by treatment with PCSK9 inhibitors has renewed focus on residual (i.e. non-LDL-C mediated) risk for cardiovascular disease (CVD). This is timely in light of the recent demonstrations of the importance of inflammatory risk factors for CVD in the Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) 12 and
Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. 13 Additionally, the importance of lipoprotein(a) (Lp(a)) in mediating CV risk has received renewed attention. It is worth mentioning that purely on the basis of data with PCSK9 inhibitors, physicians in many countries worldwide have started (re)measuring Lp(a). This highly atherogenic and pro-thrombotic lipoprotein is resistant to many lipid-lowering therapies, 14 but appears to be effectively reduced by PCSK9 inhibitors. Fasting LDL-C > _70 mg/dL or non-HDL-C > _100 mg/dL on optimal therapy
Non-HDL-C > _100 mg/dL or apolipoprotein B > _80 mg/dL. . Patients treated with evolocumab achieved mean LDL-C of 2.4 mmol/L (30 mg/dL) and this was associated with a 15% reduction (95% CI: 0.79-0.92; aRR = 2%, NNT = 50) in the primary outcome (a composite of CV death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) 2 . A secondary analysis of the data revealed that the benefits persisted at LDL-C levels <0.5 mmol/L (20 mg/dL). 17 Importantly, these benefits do not appear to be associated with excessive adverse effects and reassuringly, the rigorously conducted Evaluating PCSK9 Binding Antibody Influence on Cognitive Health in High Cardiovascular Risk Subjects (EBBINGHAUS) study found no evidence of cognitive impairment over a median of 19 months of evolocumab therapy. 18 
How should PCSKIs be used in high-risk patients?
The high acquisition cost of PCSK9 inhibitors, and the fact that high-risk individuals have been included in clinical trials has led to a discussion about the most appropriate method to stratify risk in the secondary prevention of CVD. Risk stratification is essential in order to select the patients who are most likely to benefit from treatments, and consequently to improve the cost-effectiveness of these medicines in measures such as Quality-Adjusted Life Years (QALYs) and other techniques used economic evaluations of medicines. Based on the previous analyses, PCSK9 inhibitor therapy should be considered in all high-risk patient groups where the NNT is less than 30. 19 Using the available data and sub-analyses of PCSK9 trials such patient groups have been identified by the International Lipid Expert Panel (ILEP) 20 (Table 2) ; however, further development of risk stratification algorithms would be extremely beneficial in deciding whether to initiate therapy with statin monotherapy, or to use combination therapy with statins and ezetimibe or a PCSK9 inhibitor from the outset. A risk stratification tool has previously been developed to assist therapeutic decision-making with respect to the initiation of the thrombin receptor antagonist vorapaxar in patients with ischaemic heart disease. 21 A similar scheme for decision-making with respect to PCSK9 inhibitors would likely include clinical details in addition to baseline lipid levels 19 and coronary artery calcium scores 22, 23 to enable optimal decision-making with respect to initial treatment. Based on these analyses, we should consider changes in risk stratification for secondary prevention patients and introducing the group of extremely high-risk patients to finally give clear answers as to which patients should be treated with the highest statin doses (80 mg atorvastatin and 40 mg rosuvastatin instead of the recommended ranges of 40-80 mg and 20-40 mg for atorvastatin and rosuvastatin, respectively), which patients should initiate treatment with combination therapy, and which ones might benefit the most from new therapies. 20 Furthermore, recently published findings and ongoing studies may potentially expand the scope of PCSK9Is therapy to include new patient groups including pregnancy, primary prevention, early acute coronary syndrome (less than month), and comorbidities such as chronic kidney disease. (Figure 1) . Cost-benefit analyses are likely to move in favour of PCSK9 inhibitors because of recent price reductions in these agents. In October 2018, Amgen announced that it was lowering the price of Repatha V R (evolocumab) by, by approximately 60% from $14 000 to $5850 a year. This followed an announcement in May 2018 that Regeneron and Sanofi, the manufacturers of Praluent V R (alirocumab) would reduce the price of this agent for a large number of patients. Physician familiarity with, and use of PCSK9Is is likely to increase following the publication of the recent American College of Cardiology and American Heart Association (ACC/AHA) guideline on the Management of Blood Cholesterol. 25 However, surprisingly, the guideline makes only a Class IIa recommendation for patients with atherosclerotic cardiovascular disease (ASCVD) (having two large CV outcomes studies, metaanalyses, and many other data) and only a Class IIb recommendation for patients with primary severe hypercholesterolaemia, including patients with FH (it is very unlikely any cardiovascular outcome studies for those patients will be designed). 25 With excellent clinical trial results and improving affordability, PCSK9-inhibitors are likely to be a rational choice of lipid-lowering therapy in an increasing number of very high and extremely high-risk patients. In parallel with the rapid clinical developments, PCSK9 has continued to be remarkably fruitful field of study for basic scientists. As an alternative to monoclonal antibody inhibitors to PCSK9, the ORION series of clinical trials have demonstrated safety and lipid-lowering efficacy of inclisiran, a small interfering RNA which targets the messenger RNA for PCSK9. 26 Recent preclinical studies have also shown promising results for an anti-PCSK9 antisense oligonucleotide, which reduces serum PCSK9 in a rat model. 27 The remarkably rapid progress from the identification of PCSK9 as a drug target to the development, clinical evaluation, and regulatory approval of multiple PCSK9Is is almost unique in modern medicine. This success is clearly due to close collaboration between basic scientists and clinical researchers in high-quality translational research projects. It is hoped that continued collaborative research will lead to more costeffective therapies so that the remarkable benefits of PCSK9 inhibition can be extended to as many patients as possible.
